RSV WEBInar series - Watch the webinar replay!

Lessons learned from the novavax phase 3 maternal vaccination trial

Held on November 20th, 2020
This webinar is focussed on the outcomes of the Novavax phase 3 maternal vaccination trial examining the differential effect of vaccine efficacy in HICs versus LMICs. Through interactive discussion and interview with guest speaker, prof. Shabir Madhi, and co-host, dr. Jessie Groothuis, participants were able to ask questions directly to the speaker and expand on the lessons learned from this trial in their own research.
Hosted by Prof. dr. Louis Bont and moderated and organized by: Amber Dassen, Sophie Mazur and Leyla Kragten-Tabatabaie.  

RSV awareness week 2020

9 November - 13 November

Paper of the month - October 2020

NEUTROPHILIC INFLAMMATION IN THE RESPIRATORY MUCOSA PREDISPOSES TO RSV INFECTION
Habibi MS, Thwaites RS, Chang M, Jozwik A, Paras A, Kirsebom F, Varese A, Owen A, Cuthbertson L, James P, Tunstall T, Nickle D, Hansel TT, Moffatt MF, Johansson C, Chiu C, Openshaw PJM
​
Why does RSV exposure in one individual lead to disease, while another individual does not experience symptoms at all? Besides, how can a virus reinfect individuals that already have a specific viral immune response available? In this Science paper, Habibi and his colleagues present mucosal neutrophil activation as a new factor involved in RSV susceptibility and protection. They studied the nasal mucosa by transcriptional and proteomic analyses in 58 healthy volunteers right before RSV inoculation and during the following days of infection. An active neutrophilic inflammatory status in the airways at the time of viral exposure was found to predispose to symptomatic infection. This effect might be mediated by a reduction in antiviral inflammatory responses directly after viral exposure. In addition, an early immune response to the infection with enriched IL-17 signaling and corresponding pathways was associated with protection from RSV-related symptoms. Further experiments in mice showed that chemokine induced neutrophil recruitment to the airway before viral exposure enhances disease severity and leads to an elevated cytotoxic CD8+ T cell response. These findings shed light on mechanisms of viral susceptibility and suggest new targets for RSV intervention. Furthermore, neutrophilic inflammation of the airways might not only be important in RSV infection, but in other viral respiratory diseases as well, such as in the SARS-CoV-2 infection.

Out now: RESVINET T-SHIRTs

Order a ReSViNET T-Shirt and
​contribute to our research.
On 12- 14 November 2019 ReSViNET Foundation heldt its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. ​We look back on a successful, exciting and inspiring meeting. Our special thanks to our sponsors to make this event possible and our chairs and scientific advisory board. Last but not least we thank all the speakers and participants for their contributions. ​

Recent developments in RSV Interventions

Interested in the recent developments of RSV? Then watch the REPLAY here. Prof. Louis Bont and Dr. Natalie mazur will give a full summary of the highlights of the #RSVVW19 conference in Accra.
​ 

AWARENESS OF RSV AS A GLOBAL HEALTH PROBLEM IS LACKING

To raise and spread awareness, we have launched a ‘RSV Mortality Awareness’ campaign at the start of the RSVVW2019 conference on November 12, by sharing a personal video entitled “Why we should all know about RSV” about Simone van Wyck, a mother who lost her son due to RSV. The RSV awareness video was produced in collaboration with the Bill & Melinda Gates Foundation.

ABOUT RESVINET FOUNDATION

RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. 
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!
We would like to express our sincere condolences to Neeltjes' family for their loss. Jan. 2020.
Neeltje from The Netherlands, 99 years old, participant of the RESCEU Older adults study. RSV is an important cause of pneumonia in older adults. Awareness of RSV in older adults is almost absent. Every year about 3-6% of all older adults are infected with RSV. Course of disease is most severe on older adults with severe underlying disease such as heart failure or COPD.
​

Educational activities

PeerVoice has launched three RSV activities, in collaboration with and endorsed by ReSViNET Foundation. Use the link below for more information and content of the programs.

ReSViNET Global partners